TMCnet News
Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual MeetingCAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today announced that it will present interim data from the ongoing Phase 1 dose-escalation and expansion study evaluating the company’s investigational compound, XMT-1522, in patients with HER2-expressing breast, lung and gastric tumors. The data will be presented in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Details of the poster presentation are as follows: Title: Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. Mersana will also host a conference call and webcast including principal investigator, Erika Hamilton, MD, on Monday, June 4, 2018, at 6:30 p.m. CDT to discuss the data being presented at ASCO. To access the call, please dial (877) 876-9177 and provide the Conference ID Mersana. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com. About Mersana Therapeutics Media Contact Investor Contact |